2025 Thales Data Threat Report Reveals Nearly 70% of Organizations Identify AI’s Fast-Moving Ecosystem as Top GenAI-Related Security Risk
20.5.2025 09:00:00 CEST | Business Wire | Press release
73% are investing in AI-specific security tools with either new or existing budgets. Malware remains top attack type since 2021; phishing rises to second, ransomware drops to third. 60% identified future decryption of today’s data and future encryption compromise as major concerns among quantum computing security threats.
Thales today announced the release of the 2025 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey conducted by S&P Global Market Intelligence 451 Research of more than 3,100 IT and security professionals in 20 countries across 15 industries. This year’s report found that nearly 70% of organizations view the rapid pace of AI development1 —particularly in generative AI—as the leading security concern related to its adoption, followed by lack of integrity (64%) and trustworthiness (57%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520290850/en/
©Thales
The 2025 Thales Data Threat Report results reveal a major focus on the transformative impact of AI, especially GenAI, which relies heavily on high-quality, sensitive data for functions like training, inference, and content generation. As agentic AI emerges, ensuring data quality becomes even more critical for enabling sound decision-making and actions by AI systems. Many organizations are already adopting GenAI, with a third of respondents indicating it is either being integrated or is actively transforming their operations.
Organizations Embrace GenAI, Taking on Greater Security Risks Amid Rapid Adoption
As GenAI introduces complex data security challenges and offers strategic opportunities to strengthen defenses, its growing integration marks a shift among organizations from experimentation to more mature, operational deployment. While most respondents said rapid adoption of GenAI is their top security concern, respondents in the more advanced stages of AI adoption aren’t waiting to fully secure their systems or optimize their tech stacks before forging ahead. Because the drive to achieve rapid transformation often outweighs efforts to strengthen organizational readiness, these organizations may be inadvertently creating their own biggest security vulnerabilities.
“The fast-evolving GenAI landscape is pressuring enterprises to move quickly, sometimes at the cost of caution, as they race to stay ahead of the adoption curve,” Eric Hanselman, Chief Analyst at S&P Global Market Intelligence 451 Research, said. “Many enterprises are deploying GenAI faster than they can fully understand their application architectures, compounded by the rapid spread of SaaS tools embedding GenAI capabilities, adding layers of complexity and risk.”
Seventy-three percent of respondents report investing in AI-specific security tools, either through new budgets or by reallocating existing resources. Those prioritizing AI security are diversifying their approaches: over two-thirds have acquired tools from their cloud providers, three in five are leveraging established security vendors, and nearly half are turning to new or emerging startups. Notably, security for generative AI has quickly risen as a top spending priority, securing the second spot in ranked-choice voting, just behind cloud security. This shift underscores the growing recognition of AI-driven risks and the need for specialized defenses to mitigate them.
Data Breaches Show Modest Decline, Though Threats Remain Elevated
While data breaches remain a significant concern, their frequency has slightly decreased over the past few years. In 2021, 56% of surveyed enterprises reported experiencing a breach, but that figure has dropped to 45% in 2025. Additionally, the percentage of respondents reporting a breach within the last 12 months has fallen from 23% in 2021 to just 14% in 2025.
Malware continues to lead as the most prevalent threat, maintaining its top position since 2021. Phishing climbed to second place, overtaking ransomware, which now ranks third. When it comes to the most concerning threat actors, external sources dominate—hacktivists hold the top spot, followed by nation-state actors. Human error, while still significant, has dropped to third, down one position from the previous year.
Vendors Pressed on Post-Quantum Readiness as Encryption Strategies Are Reassessed
The 2025 Thales Data Threat Report reveals that most organizations are increasingly concerned about quantum-related security risks. The top threat, cited by 63% of respondents, is future encryption compromise—the risk that quantum computers could eventually break current or future encryption algorithms, exposing data once considered secure. Close behind, 61% identified key distribution vulnerabilities, where quantum advancements could undermine the secure exchange of encryption keys. Additionally, 58% highlighted the “harvest now, decrypt later” (HNDL) threat, where encrypted data intercepted today could be decrypted in the future. In response, half of organizations are assessing their encryption strategies, and 60% are actively prototyping or evaluating post-quantum cryptography (PQC) solutions. Only one-third, however, are placing their trust in telecom or cloud providers to manage the transition.
“The clock is ticking on post-quantum readiness. It’s encouraging that three out of five organizations are already prototyping new ciphers, but deployment timelines are tight and falling behind could leave critical data exposed,” Todd Moore, Global Vice President, Data Security Products at Thales, said. “Even with clear timelines for transitioning to PQC algorithms, the pace of encryption change has been slower than expected due to a mix of legacy systems, complexity, and the challenge of balancing innovation with security.”
While this year’s survey results indicate improvements in security posture, much more is needed to elevate operational data security to fully support the capabilities of emerging technologies such as GenAI and to pave the way for future innovations.
For more information please join our webinar hosted by Eric Hanselman, Chief Analyst at S&P Global 451 Research.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.
The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.
Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
1 This finding relates to the fast changes in the GenAI ecosystem which encompasses the full set of vendors and technologies in GenAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520290850/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom